FDA advisory panel to debate allowing compounding pharmacies to produce unapproved peptides

FDA advisers will convene on Thursday and Friday to discuss a proposal that would let compounding pharmacies manufacture seven synthetic peptides that are currently classified as unsafe for compounding.

Proponents argue that allowing pharmacies to produce these peptides could move sales from the unregulated gray market into a more controlled environment, potentially improving product quality and patient safety.

FDA staff and many panel members, however, warn that the peptides lack robust clinical data and that expanding compounding could expose patients to unknown risks, leading to a sharp disagreement between peptide advocates and regulators.

The panel’s decision could shape how these compounds are accessed in the United States and may influence future regulatory approaches to emerging peptide therapies.